Core Framework & Diagram What Are Immune Predictive Models?

Yes, and this is a risk all prediction models must honestly face. No prediction model can achieve one hundred percent accuracy — current best models have approximately seventy to eighty-five percent accuracy on validation datasets, with still considerable proportions of wrong predictions. This means: prediction models can only serve as auxiliary tools, not the final basis for decisions; models' prediction uncertainty should be transparently communicated to doctors and patients; for 'model predicts non-response but patient strongly wishes to try' situations, humanized decision processes need to be established — algorithms can't be the final 'judge.'

This is one of current models' biggest weaknesses. ML prediction models rely on large amounts of training data, while rare disease patient groups are too small to accumulate sufficient training samples. Solutions include: transfer learning (transferring knowledge from large similar disease datasets to rare disease small datasets), synthetic data generation (expanding training samples with GAN generative models), and mechanistic models (don't depend on large amounts of data, but need sufficient mechanism understanding).

This is a rapidly developing cross-disciplinary area. HRV, skin conductance, body temperature, sleep quality, and other wearable indicators have been proven to have statistical associations with certain immune markers (like inflammation levels, stress responses). But currently these associations' signal strength and specificity aren't sufficient for standalone clinical-grade immune state prediction. Multi-modal predictive models combining wearable data with periodic blood immunomics data are a promising research direction.

For autoimmune diseases with sufficient data accumulation (like SLE, RA), prediction models have shown disease flare warning capability (predicting high-risk periods weeks in advance) and treatment response prediction in clinical research. The clinical translation of these models can reduce unnecessary treatment switching, directly improving patient outcomes.